79 related articles for article (PubMed ID: 7234217)
1. [Cytogenetic studies for detection of tumour strain lines of ovarian cancer cells (author's transl)].
Kademann R; Marx B; Krafft W; Kademann J; Preibsch W; Behling H; Brückmann D
Zentralbl Gynakol; 1981; 103(3):176-80. PubMed ID: 7234217
[TBL] [Abstract][Full Text] [Related]
2. [Chromosome aberrations in oncobiogram - cytogenetic studies into aberration frequency following trenimon treatment in vitro (author's transl)].
Weise W; Kosmowski A
Zentralbl Gynakol; 1979; 101(20):1297-307. PubMed ID: 539207
[TBL] [Abstract][Full Text] [Related]
3. [Heterochromatin polymorphism of A1 chromosome in patients with ovarian carcinoma (author's transl)].
Adomat W; Weise W
Zentralbl Gynakol; 1981; 103(15):865-73. PubMed ID: 7304018
[TBL] [Abstract][Full Text] [Related]
4. Cytogenetic and molecular cytogenetic characterization of the stable ovarian carcinoma cell line (OvBH-1).
Schlade-Bartusiak K; Sasiadek MM; Bar JK; Urbschat S; Blin N; Montenarh M; Harłozińska-Szmyrka A
Cancer Genet Cytogenet; 2006 Jan; 164(1):10-5. PubMed ID: 16364757
[TBL] [Abstract][Full Text] [Related]
5. Cytogenetic and cell cycle studies in metastatic cells from ovarian carcinomas.
Augustus M; Brüderlein S; Gebhart E
Anticancer Res; 1986; 6(2):283-9. PubMed ID: 3707064
[TBL] [Abstract][Full Text] [Related]
6. Preferential involvement of chromosome 11 as add(11)(p15) in ovarian cancer: is it a common cytogenetic abnormality in cancer?
Panani AD
Cancer Lett; 2007 Dec; 258(2):262-7. PubMed ID: 17945413
[TBL] [Abstract][Full Text] [Related]
7. Numerical abnormalities of chromosomes 1, 11, 17, and X are associated with stromal invasion in serous and mucinous epithelial ovarian tumours.
Evans MF; McDicken IW; Herrington CS
J Pathol; 1999 Sep; 189(1):53-9. PubMed ID: 10451488
[TBL] [Abstract][Full Text] [Related]
8. Detection of circulating tumour cells in patients with breast or ovarian cancer by molecular cytogenetics.
Engel H; Kleespies C; Friedrich J; Breidenbach M; Kallenborn A; Schöndorf T; Kolhagen H; Mallmann P
Br J Cancer; 1999 Dec; 81(7):1165-73. PubMed ID: 10584878
[TBL] [Abstract][Full Text] [Related]
9. Recurrent cytogenetic aberrations in human ovarian carcinomas.
Kiechle-Schwarz M; Bauknecht T; Schmidt J; Walz L; Pfleiderer A
Cancer Detect Prev; 1995; 19(3):234-43. PubMed ID: 7750111
[TBL] [Abstract][Full Text] [Related]
10. Characterization of highly radiosensitive cell lines from a human ovarian small-cell cancer.
Hanson JA; Parry EM; Gibbs AR; Court JB; Pour-Faizi MA; Kerby IJ; Bean EA
Gynecol Oncol; 1997 Nov; 67(2):147-53. PubMed ID: 9367698
[TBL] [Abstract][Full Text] [Related]
11. Comparative genomic hybridization analysis of chromosomal changes occurring during development of acquired resistance to cisplatin in human ovarian carcinoma cells.
Wasenius VM; Jekunen A; Monni O; Joensuu H; Aebi S; Howell SB; Knuutila S
Genes Chromosomes Cancer; 1997 Apr; 18(4):286-91. PubMed ID: 9087568
[TBL] [Abstract][Full Text] [Related]
12. Effect of culture conditions on the chemosensitivity of ovarian cancer cell lines.
Fernando A; Glaysher S; Conroy M; Pekalski M; Smith J; Knight LA; Di Nicolantonio F; Cree IA
Anticancer Drugs; 2006 Sep; 17(8):913-9. PubMed ID: 16940801
[TBL] [Abstract][Full Text] [Related]
13. Karyological and isoenzyme characterization of established human sarcoma cell lines.
Phan Thu A; Zajac V; Kuliffay P; Popović M
Neoplasma; 1980; 27(5):557-66. PubMed ID: 6262670
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal evaluation of cytogenetic aberrations in prostatic cancer: tumours that recur in time display an intermediate genetic status between non-persistent and metastatic tumours.
Alers JC; Krijtenburg PJ; Hop WC; Bolle WA; Schröder FH; van der Kwast TH; Bosman FT; van Dekken H
J Pathol; 1998 Jul; 185(3):273-83. PubMed ID: 9771481
[TBL] [Abstract][Full Text] [Related]
15. [Establishment of human ovarian carcinoma cell lines with directional highly lymphatic metastasis and study of their biological characteristics].
Ruan HY; Li DR; Li L; Guan X; Zhang W
Zhonghua Fu Chan Ke Za Zhi; 2007 Jul; 42(7):482-6. PubMed ID: 17961340
[TBL] [Abstract][Full Text] [Related]
16. Human ovarian cancer, cell lines, and primary ascites cells express the human Mullerian inhibiting substance (MIS) type II receptor, bind, and are responsive to MIS.
Masiakos PT; MacLaughlin DT; Maheswaran S; Teixeira J; Fuller AF; Shah PC; Kehas DJ; Kenneally MK; Dombkowski DM; Ha TU; Preffer FI; Donahoe PK
Clin Cancer Res; 1999 Nov; 5(11):3488-99. PubMed ID: 10589763
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the candidate 8p21 tumour suppressor, BNIP3L, in breast and ovarian cancer.
Lai J; Flanagan J; Phillips WA; Chenevix-Trench G; Arnold J
Br J Cancer; 2003 Jan; 88(2):270-6. PubMed ID: 12610513
[TBL] [Abstract][Full Text] [Related]
18. [Cytogenetic findings in ovarian tumors (author's transl)].
Knörr-Gärtner H; Schuhmann R; Uebele-Kallhardt B
Verh Dtsch Ges Pathol; 1973; 57():203-7. PubMed ID: 4142176
[No Abstract] [Full Text] [Related]
19. Spontaneous transformation of rat ovarian surface epithelial cells results in well to poorly differentiated tumors with a parallel range of cytogenetic complexity.
Testa JR; Getts LA; Salazar H; Liu Z; Handel LM; Godwin AK; Hamilton TC
Cancer Res; 1994 May; 54(10):2778-84. PubMed ID: 8168110
[TBL] [Abstract][Full Text] [Related]
20. Patterns of expression of chromosome 17 genes in primary cultures of normal ovarian surface epithelia and epithelial ovarian cancer cell lines.
Presneau N; Mes-Masson AM; Ge B; Provencher D; Hudson TJ; Tonin PN
Oncogene; 2003 Mar; 22(10):1568-79. PubMed ID: 12629520
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
